Replies to post #54990 on Biotech Values

[walldiver]

DNDN -- Doc, docetaxel had already been approved for breast cancer, so a lot of patients in both arms were able to take it off label. In the 9901 trial, 37% of the pts in the Provenge arm got docetaxel, while 49% of the control arm took it. Supposedly, the patients in the Provenge arm averaged fewer cycles of docetaxel than those in the control arm.